Head-To-Head Comparison: OptiNose (NASDAQ:OPTN) and Aoxing Pharmaceutical (NASDAQ:AOXG)
Aoxing Pharmaceutical (OTCMKTS:AOXG) and OptiNose (NASDAQ:OPTN) are both medical companies, but which is the superior stock? We will compare the two companies based on the strength of their risk, institutional ownership, valuation, profitability, dividends, earnings and analyst recommendations.
Earnings and Valuation
This table compares Aoxing Pharmaceutical and OptiNose’s top-line revenue, earnings per share and valuation.
|Gross Revenue||Price/Sales Ratio||Net Income||Earnings Per Share||Price/Earnings Ratio|
|OptiNose||$7.07 million||47.93||-$106.66 million||($2.68)||-3.04|
This is a summary of current ratings and target prices for Aoxing Pharmaceutical and OptiNose, as reported by MarketBeat.com.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
OptiNose has a consensus price target of $25.00, suggesting a potential upside of 206.75%. Given OptiNose’s higher possible upside, analysts plainly believe OptiNose is more favorable than Aoxing Pharmaceutical.
This table compares Aoxing Pharmaceutical and OptiNose’s net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
Insider and Institutional Ownership
68.4% of OptiNose shares are owned by institutional investors. 17.8% of Aoxing Pharmaceutical shares are owned by insiders. Comparatively, 44.3% of OptiNose shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.
Risk and Volatility
Aoxing Pharmaceutical has a beta of 5.45, meaning that its share price is 445% more volatile than the S&P 500. Comparatively, OptiNose has a beta of 0.74, meaning that its share price is 26% less volatile than the S&P 500.
OptiNose beats Aoxing Pharmaceutical on 5 of the 9 factors compared between the two stocks.
About Aoxing Pharmaceutical
Aoxing Pharmaceutical Company, Inc. a specialty pharmaceutical company, engages in research and development, manufacture, and distribution of narcotic, pain-management, and addiction treatment pharmaceutical products primarily in the People's Republic of China. The company's principal products include Zhongtong'an, a capsule of herbal extraction for the indication of oral and dental pain; and Yiqi Qiangshen Granule, an OTC herbal extraction for tonifying qi and empowering body, and promoting blood circulation to remove meridian obstruction, as well as Tilidine hydrochloride, an orally-absorbed synthetic narcotic analgesic tablet used in 50mg or 100mg dosage for relief of acute, moderate to severe pain, and chronic cancer-related pain. Its products under development comprise Oxycodone and Acetaminophen tablets and capsules, which has completed clinical trials for the treatment of acute and chronic pain; Buprenorphine/Naloxone, a sublingual combo tablet that has completed Phase II clinical trials for the treatment of opioid dependence; and Tilidine/Naloxone, a compound capsule which is in Phase II clinical trial to treat acute and chronic pain. The company was formerly known as China Aoxing Pharmaceutical Company, Inc. and changed its name to Aoxing Pharmaceutical Company, Inc. in March 2010. Aoxing Pharmaceutical Company, Inc. is headquartered in Shijiazhuang, China.
OptiNose, Inc., a specialty pharmaceutical company, focuses on the development and commercialization of products for patients treated by ear, nose, and throat; and allergy specialists in the United States. The company offers XHANCE, a therapeutic product utilizing its proprietary optinose exhalation delivery system that delivers a topically-acting and anti-inflammatory corticosteroid for the treatment of chronic rhinosinusitis with and without nasal polyps. It also markets Onzetra Xsail (AVP-825) for the acute treatment of migraines in adults through its license agreement with Avanir Pharmaceuticals, Inc. In addition, the company is developing XHANCE for the treatment of chronic sinusitis; and OPN-300 for the treatment of Prader-Willi syndrome, a rare genetic obesity disorder, as well as autism spectrum disorder. It has a license agreement with Inexia Limited to manufacture, import, and sale products containing orexin receptor agonist and/or orexin receptor positive modulator molecules for the treatment, diagnosis, or prevention of human diseases or conditions associated primarily with orexin receptor agonism and orexin receptor positive modulation. OptiNose, Inc. was founded in 2010 and is headquartered in Yardley, Pennsylvania.
Receive News & Ratings for Aoxing Pharmaceutical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aoxing Pharmaceutical and related companies with MarketBeat.com's FREE daily email newsletter.